Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Biotech
JPM26: Gilead eyes new deals from a 'position of strength'
Across virology, oncology and inflammation, Gilead has "the luxury of being selective" in the external assets it considers adding to its pipeline.
Darren Incorvaia
Jan 14, 2026 3:30am
Lilly buys inflammation biotech Ventyx for $1.2B
Jan 8, 2026 7:01am
Tiziana to spin out IL-6 drug, cites pharma interest in modality
Dec 2, 2025 8:45am
Inflammation biotech Evommune heads to NYSE with $150M IPO
Nov 6, 2025 7:00am
Neurocrine pens $880M pact with TransThera for immunology target
Nov 3, 2025 5:42am
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
